What TG Therapeutics, Inc. told the SEC could break it.

TG relies on sole-source, often single-site suppliers for the starting materials, intermediates, API/drug substance, drug product and other materials used in BRIUMVI and its pipeline; loss or disruption of any one of these single-source suppliers could significantly harm its business with no near-term alternative.

“The third parties upon whom we rely for the supply of starting materials, intermediates, active pharmaceutical ingredient (API)/drug substance, drug product, and other materials used in our drug candidates are our sole source of supply, and the loss or disruption of any of these suppliers could significantly harm our business.”

TG's sole supplier of bulk drug substance is located outside the U.S., making tariffs an inventoriable cost that could raise BRIUMVI's cost base; the threat is amplified by a Section 232 national-security investigation into pharmaceutical imports and an announced 100% tariff on branded/patented drugs from manufacturers without U.S. manufacturing.

“The United States and other countries have recently imposed, and may continue to impose, new tariffs. Tariffs are an inventoriable cost, and the Company's sole supplier of bulk drug substance is located outside of the U.S. While the tariffs imposed to date have not had a material effect on the Company's business or results of operations, the Company continues to evaluate their potential impact on its business and results of operations going forward.”